Alkem Laboratories Ltd
NSE: ALKEM BSE: 539523
₹5402.50
(-7.97%)
Fri, 13 Feb 2026, 04:16 pm
Market Cap700.45B
PE Ratio27.36
Dividend0.77
Health Technology
Pharmaceuticals: Major
24.5KAlkem Laboratories Analysis
dividend
- Dividends paid are well covered by earnings (3.8x coverage).
- Dividends after 3 years are expected to be well covered by earnings (4.7x coverage).
- Alkem Laboratories's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividend payments have increased, but Alkem Laboratories only paid a dividend in the past 4 years.
- Alkem Laboratories has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
- Alkem Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for Alkem Laboratories is expected to increase by more than 50% in 2 years time.
- Alkem Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Alkem Laboratories's earnings are expected to exceed the low risk growth rate next year.
- Alkem Laboratories's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in Alkem Laboratories's performance (ROE) is expected over the next 3 years.
- Alkem Laboratories's revenue growth is expected to exceed the India market average.
- Alkem Laboratories's earnings are expected to grow by 13.5% yearly, however this is not considered high growth (20% yearly).
- Alkem Laboratories's earnings growth is positive but not above the India market average.
- Alkem Laboratories's net income is expected to increase but not above the 50% threshold in 2 years time.
- Alkem Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Alkem Laboratories's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Alkem Laboratories's revenue is expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).
health
- Alkem Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Alkem Laboratories is profitable, therefore cash runway is not a concern.
- Alkem Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (35.3%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 3.3x debt.
- Alkem Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (42.3% vs 26.3% today).
- Interest payments on debt are well covered by earnings (EBIT is 18.8x coverage).
- Alkem Laboratories's level of debt (26.3%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Alkem Laboratories board of directors is about average.
- Dhananjay's remuneration is about average for companies of similar size in India.
- Dhananjay's compensation has been consistent with company performance over the past year, both up more than 20%.
past
- Alkem Laboratories's 1-year earnings growth exceeds its 5-year average (48.1% vs 9%)
- Alkem Laboratories's year on year earnings growth rate has been positive over the past 5 years.
- Alkem Laboratories used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Alkem Laboratories's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (48.1% vs 22.7%).
- Alkem Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Alkem Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- ALKEM outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- ALKEM outperformed the Market in India which returned -14.5% over the past year.
- Alkem Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Alkem Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Alkem Laboratories is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Alkem Laboratories is poor value based on expected growth next year.
- Alkem Laboratories is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Alkem Laboratories is overvalued based on earnings compared to the India market.
- NSEI:ALKEM is down -3.2% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:ALKEM is down -3.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800